Evidence map›Paper›PMID 38271786›Full record

ArticleESMO open2024

Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era.

G Hagopian, X Jiang, C Grant, D Brazel, P Kumar, M Yamamoto, J Jakowatz, W Chow, T Tran, W Shen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

G HagopianDepartment of Medicine, University of California Irvine Medical Center, Orange.
X JiangDepartment of Statistics, University of California Irvine, Irvine.
C GrantDepartment of Medicine, University of California Irvine Medical Center, Orange.
D BrazelDepartment of Medicine, University of California Irvine Medical Center, Orange.
P KumarDepartment of Medicine, University of California Irvine Medical Center, Orange.
M YamamotoDivision of Surgical Oncology, Department of Surgery, University of California Irvine Medical Center, Orange.
J JakowatzDivision of Surgical Oncology, Department of Surgery, University of California Irvine Medical Center, Orange.
W ChowDivision of Hematology and Oncology, Department of Medicine, University of California Irvine Medical Center, Orange.
T TranDivision of Surgical Oncology, Department of Surgery, University of California Irvine Medical Center, Orange.
W ShenDepartment of Statistics, University of California Irvine, Irvine.
J MoyersThe Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, USA. Electronic address: jmoyers@theangelesclinic.org.
University of California, Irvine Medical Center · USUniversity of California, Irvine · USAngeles Clinic and Research Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCheckpoint inhibitors have shown improvement in recurrence-free survival in the post-operative setting for node-positive melanoma and were first approved in late 2015. However, single-agent checkpoint therapies have yet to show benefit to overall survival (OS) for lower-risk stage III cancers. We evaluated the OS benefit of post-operative immunotherapy in the National Cancer Database (NCDB). PATIENTS AND

methodsPatient cases were selected from the NCDB 2020 Participant Use File. Patients diagnosed with stage III cutaneous melanoma between 2016 and 2019 who underwent definitive resection for their melanoma were included. OS between those who received post-operative immunotherapy within 84 days of surgery and those who did not was analyzed by the Kaplan-Meier method. Demographic and clinical characteristics between the two groups were compared via Cox proportional hazard models.

results14 978 patients with stage III melanoma were included. Of those, 34.9% (n = 5234) received post-operative immunotherapy and 65.1% (n = 9744) did not. Using the American Joint Committee on Cancer version 8 (AJCCv8) staging, 36-month survival was significantly higher in patients who received post-operative immunotherapy compared to no post-operative systemic therapy in those diagnosed with stage IIIB (88.0% versus 84.7%, P = 0.011), IIIC (75.6% versus 68.1%, P < 0.001), or IIID (59.2% versus 48.4%, P = 0.002). No significant improvement in 36-month survival was seen in patients who received post-operative immunotherapy in patients with stage IIIA disease (93.0% versus 92.2%, P = 0.218).

conclusionsPost-operative immunotherapy had an OS benefit in patients with AJCCv8 stage IIIB, IIIC, and IIID disease, but had no significant survival benefit for patients with stage IIIA melanomas.

Indexed as

MelanomaSkin NeoplasmsHumansImmunotherapyNeoplasm StagingProportional Hazards Modelsadjuvant immunotherapyimmunotherapymelanoma

Identifiers

PMID38271786
PMCPMC10937207
OpenAlexW4391206998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.